A new collaborative effort between Mayo Clinical Laboratories and Amprion will expand access to the diagnostic company’s SAAmplify–αSYN test — designed to detect the presence of abnormal alpha-synuclein protein in people suspected of having neurodegenerative diseases — across the U.S., according to a joint press release.
Lecigon, an intestinal gel formulation of levodopa, entacapone, and carbidopa, provided sustained motor symptom control for people with advanced Parkinson’s disease, according to interim, one-year analyses from a real-world study in Europe. The treatment, which is approved in several European countries and Australia, but not the U.S.,…
Researchers at the University of Delaware have developed a model that combines artificial intelligence with magnetic resonance elastography (MRE) to measure brain stiffness and volume for predicting brain age. MRE is a noninvasive method that can measure changes in brain stiffness by using a gentle vibration of a person’s head…
Irlab Therapeutics is moving its oral candidate, IRL757, into a Phase 1b clinical study to assess its safety and explore early signs of efficacy in treating apathy in people with Parkinson’s disease. Patient enrollment is expected to begin in the second half of 2025. Financial support for the trial…
A rare mutation in the LRRK2 gene found in 17 individuals with Parkinson’s disease or a family history of Parkinson’s — all of European ancestry with a shared genetic background — appears to be a likely cause of the condition, according to a study of thousands of people. The…
Older adults with tremor are three times more likely than those in the general elderly population to develop Parkinson’s disease — especially if they act out their dreams while sleeping or experience new-onset rest tremor — a study from China has found. That study aimed “to explore predictive factors”…
Physical exercise eased signs of a type of iron-mediated cell death called ferroptosis in microglia and improved neurological function in mouse models of Parkinson’s disease, a study finds. Microglia are a type of nervous system support cell that’s believed to be important in the neurodegenerative disease. When ferroptosis was…
The Michael J. Fox Foundation (MJFF) has brought together top experts from around the world to speed up research on five lesser-known biological targets in Parkinson’s disease in an effort to identify promising treatment opportunities. Seven more will be explored in a future phase. This effort is part…
NDC-0524, an experimental antibody that Nitrase Therapeutics is developing as a treatment for people with Parkinson’s disease, is expected to enter clinical testing in the fourth quarter of 2025, or before the end of the year, according to a company press release. The antibody, which targets nitrated…
Newronika is preparing for the commercial launch of AlphaDBS — a next-generation adaptive deep brain stimulation (DBS) system for treating Parkinson’s disease — at selected markets in Europe this year, following CE Mark approval in the European Union. That’s according to a company press release, in which…
Get regular updates to your inbox.
